Black Diamond reports Phase 2 silevertinib data, plans FDA meeting on pivotal path
Black Diamond said no patients developed new brain metastases in a Phase 2 lung cancer trial and it will seek FDA feedback on pivotal development in the fourth quarter of 2026.
SEC filing